Lakefront is a clean dislocation candidate: the market prices the company below its guided year-end cash and financial investments, while gamgertamig gives shareholders a real autoimmune T-cell engager option. The hard floor is not accounting book value alone; management says at least EUR 1.6B should remain after funding the portfolio to first gamgertamig approval.
Scenario weights lean bull/base only because the downside is anchored by cash and the catalyst path is dated. The fair value is still built bottom-up from cash, POS-weighted rNPV, buyback accretion and explicit reserves. Not investment advice.
| Component | Assumption | $/share |
|---|---|---|
| Guided YE2026 cash/investments | EUR 2.0125B midpoint of EUR 1.975B-2.050B guidance / 64.98M shares | +30.97 |
| Gamgertamig autoimmune rNPV | EUR 1.8B peak sales x 45% contribution x 5.0x PV factor x 20% POS / 64.98M shares | +12.47 |
| GLPG3667 TYK2 option | EUR 650M peak sales x 35% contribution x 4.0x PV factor x 12% POS / 64.98M shares | +1.68 |
| BD/capital allocation option | 15% probability x EUR 500M value creation from remaining dry powder / 64.98M shares | +1.15 |
| EUR 50M buyback accretion | Repurchase at EUR 25.66 retires about 1.95M shares; NAV accretion rounded | +0.40 |
| FX and cash-burn reserve | USD cash exposure plus EUR 125M-175M cell-therapy wind-down variability | -2.20 |
| Clinical/deal execution reserve | EUR 95M reserve for Phase 2/registrational execution and Ouro integration risk | -1.46 |
| FV base case | Explicit sum of components above | EUR 43.01 |
Insider/governance check: MarketScreener shows small January 2026 insider purchases by directors and no material insider sale over EUR 500K in the checked table. Litigation searches did not surface a current LKFT securities class action, short-seller report, SEC investigation or going-concern warning in the last 90 days.
| Item | FY2024 | FY2025 | H1 2026 | FY2026E | Guidance / note |
|---|---|---|---|---|---|
| Total net revenues | EUR 275.6M | EUR 1,112.2M | EUR 18.6M | EUR 117.2M consensus | 2025 distorted by collaboration income |
| Operating income/loss | EUR -187.1M | EUR 295.1M | EUR -107.2M | EUR -172.3M consensus | Reset year after Ouro deal |
| Net income/loss | EUR 74.1M | EUR 320.9M | EUR 16.6M | EUR -40.7M consensus | H1 benefited from financial income |
| Cash/investments | EUR 3,317.8M | EUR 2,998.0M | EUR 2,239.5M | EUR 1,975-2,050M | Guided year-end cash range |
| Net cash / debt | Net cash | Net cash | Debt minimal | Net cash | StockAnalysis shows Debt/Equity 0.00 |
| Metric | FY2024 | FY2025 | Q1 2026 | Q2 2026 / H1 | YE2026E |
|---|---|---|---|---|---|
| Revenue / net revenue (EUR M) | 275.6 | 1,112.2 | N/D | 18.6 H1 | 117.2 consensus |
| Operating income/loss (EUR M) | -187.1 | 295.1 | N/D | -107.2 H1 | -172.3 consensus |
| Net income/loss (EUR M) | 74.1 | 320.9 | N/D | 16.6 H1 | -40.7 consensus |
| Cash/investments EOP (EUR M) | 3,317.8 | 2,998.0 | N/D | 2,239.5 | 1,975-2,050 |
Business model - cash-backed immunology redeployment
Gamgertamig Phase 2 now, 2027 registrational plan lead asset Potential first/best-in-class autoimmune T-cell engager. Orphan/Fast Track designations support speed, but pivotal data are still ahead. Cash and BD engine EUR 1.6B+ after first-approval funding floor The balance sheet is the asymmetry anchor. Value creation depends on not overpaying for new assets. Legacy pipeline / GLPG3667 Phase 2 / option value option TYK2 and legacy cell-therapy assets are secondary; they deserve option value but not core fair-value control.
Legal, regulatory and risk analysis
SWOT analysis
- +Cash and financial investments exceed market cap.
- +At least EUR 1.6B expected after funding the lead asset to first approval.
- +Gilead-linked Ouro transaction brings external validation and immunology focus.
- −Core operating business is loss-making during the reset year.
- −Fair value is highly sensitive to POS assumptions for gamgertamig.
- −Collaboration revenue makes historical income statements hard to normalize.
- →2027 registrational trials could convert cash discount into pipeline credit.
- →Buybacks below cash value are accretive and signal discipline.
- →Additional autoimmune indications can expand the rNPV tree.
- !Weak clinical durability or safety would collapse pipeline value.
- !Poor M&A could destroy the net-cash discount thesis.
- !FX swings can obscure underlying cash preservation.
Summary by assessment area
- Hard cash floor sits close to the current price.
- Base FV is driven by cash plus visible clinical optionality.
- Gamgertamig is the right kind of asset, but still pre-registrational.
- 2027 trial starts are the key validation step.
- Buyback is positive; future BD pricing is the major governance test.
- A cash-rich biotech can become either disciplined or expensive very quickly.
Sources: Lakefront H1 2026 results and SEC 6-K (Aug 10, 2026); StockAnalysis AMS:LKFT price/history/statistics/forecast; Vienna Stock Exchange historical LKFT quote; MarketBeat LKFT short interest; Lakefront buyback and own-share releases; MarketScreener insider transactions; OCC memo on GLPG to LKFT name/symbol change; Yahoo/MarketBeat and Lakefront releases on gamgertamig orphan designation and 2027 registrational-trial plans. Market data - last verified close 2026-10-01: LKFT EUR 25.66, market cap ~EUR 1.67B, 52W range EUR 22.32-EUR 32.74, 64.98M shares outstanding. Short interest: 5.34% float. This document is for informational purposes only and does not constitute financial or investment advice.